Citation Report

List of articles citing

Phosphodiesterase type 5 inhibitors for erectile dysfunction

DOI: 10.1111/j.1464-410x.2005.05614.x
BJU International, 2005, 96, 257-80.

#	Paper	IF	Citations
173	Existing and future pharmacotherapy for erectile dysfunction. **2006**, 16, 1215-1222		
172	Effect of regular phosphodiesterase type 5 inhibition in hypertension. *Hypertension*, **2006**, 48, 622-7	8.5	80
171	Synthesis, radiolabeling and in vivo evaluation of [11C]RAL-01, a potential phosphodiesterase 5 radioligand. **2006**, 33, 593-7		31
170	Bibliography. Current world literature. Reconstructive surgery. **2006**, 16, 460-3		
169	Medicinal Chemistry of PDE4 Inhibitors. **2006**,		
168	Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. *BJU International*, **2006**, 98, 1259-63	5.6	136
167	Molecular mechanisms of detrusor and corporal myocyte contraction: identifying targets for pharmacotherapy of bladder and erectile dysfunction. **2006**, 147 Suppl 2, S41-55		30
166	Treatment options for autonomic neuropathies. **2006**, 8, 119-32		10
165	Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. **2006**, 50, 1086-94; discussion 1094-5		26
164	Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. **2006**, 10, 445-57		26
163	Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. **2006**, 12, 3459-65		50
162	Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. **2006**, 12, 3467-84		47
161	Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. **2007**, 293, R2081-9		32
160	Lack of central nitric oxide triggers erectile dysfunction in diabetes. **2007**, 292, R1158-64		28
159	Chronic sildenafil in men with diabetes and erectile dysfunction. **2007**, 3, 451-64		24
158	Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea. **2007**, 6, 423-30		4
157	Reactive oxygen species and erectile dysfunction: possible role of NADPH oxidase. **2007**, 19, 265-80		56

156	Sildenafil reduces postoperative adhesion formation in a rat uterine horn model. **2007**, 135, 183-7		16
155	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. **2007**, 34, 507-15, vi		23
154	Depression and erectile dysfunction. **2007**, 34, 565-74, vii		33
153	Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?. **2007**, 262, 89-97		26
152	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. **2007**, 3, 527-542		1
151	Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. **2007**, 584, 137-47		16
150	Sildenafil inhibits the up-regulation of phosphodiesterase type 5 elicited with nicotine and tumour necrosis factor-alpha in cavernosal vascular smooth muscle cells: mediation by superoxide. *BJU International*, **2007**, 99, 612-8	5.6	38
149	Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. *BJU International*, **2008**, 101, 203-10	5.6	120
148	Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. *Asian Journal of Andrology*, **2007**, 9, 760-70	2.8	16
147	Phosphodiesterase type 5 inhibitors: the day after. **2007**, 51, 75-88; discussion 89		73
146	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. **2007**, 52, 990-1005		45
145	Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. *Journal of Sexual Medicine*, **2007**, 4, 137-144	1.1	9
144	Optimizing response to phosphodiesterase type 5 inhibitors. **2007**, 4, 1-6		1
143	Development of LC/MS/MS assay for the determination of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-o (SK3530) in human plasma: application to a clinical pharmacokinetic study. **2007**, 45, 176-184		10
142	Phosphodiesterase 5 inhibition in essential hypertension. **2008**, 10, 52-7		27
141	Effect of phospodiesterase 5 inhibitors on apoptosis and nitric oxide synthases in testis torsion: an experimental study. **2008**, 24, 205-11		25
140	Homocysteine and copper interact to promote type 5 phosphodiesterase expression in rabbit cavernosal smooth muscle cells. *Asian Journal of Andrology*, **2008**, 10, 905-13	2.8	15
139	Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. **2008**, 154, 787-96		36

138	Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review. *BJU International*, **2008**, 102, 426-31	5.6	19
137	The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. *Journal of Sexual Medicine*, **2008**, 5, 946-953	1.1	56
136	PDE4 associates with different scaffolding proteins: modulating interactions as treatment for certain diseases. *Handbook of Experimental Pharmacology*, **2008**, 125-66	3.2	34
135	Phosphodiesterase 5 inhibitors may facilitate bone fracture recovery. **2008**, 70, 461-2		4
134	The use of phosphodiesterase 5 inhibitors with concomitant medications. **2008**, 31, 799-808		49
133	Surgical therapy for the treatment of erectile dysfunction. **2008**, 5, 174-5		3
132	Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. **2008**, 17, 855-64		16
131	Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction. **2008**, 4, 24-30		9
130	New horizons in erectile and endothelial dysfunction research and therapies. **2008**, 20 Suppl 2, S2-8		19
129	UnderstandingindividualsTresponse to erectile dysfunction. **2008**, 20 Suppl 2, S15-20		6
128	Tadalafil in the treatment of erectile dysfunction. **2008**, 4, 1315-30		57
127	The many faces of testosterone. **2007**, 2, 567-76		47
126	Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation. **2009**, 12, 58-61		2
125	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. **2009**, 16, 3480-675		117
124	Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. *Journal of Sexual Medicine*, **2009**, 6, 2039-48	1.1	51
123	Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate. **2009**, 67, 403-12		9
122	Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects. **2009**, 36, 358-66		5
121	High performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of vardenafil, sildenafil, tadalafil, testosterone and local anesthetics in cosmetic creams sold on the Internet web sites. **2009**, 50, 362-9		52

120	Cyclic GMP-hydrolyzing phosphodiesterases. *Handbook of Experimental Pharmacology*, **2009**, 367-408	3.2	28
119	cGMP: Generators, Effectors and Therapeutic Implications. *Handbook of Experimental Pharmacology* , **2009**,	3.2	13
118	The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 155-60	4	22
117	Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. **2009**, 19, 7-12		16
116	New Pharmacologic Horizons in the Treatment of Benign Prostatic Hyperplasia. **2010**, 5, 262-270		1
115	Failure of PDE5 inhibitor use: a case of nonresponder? (CME). *Journal of Sexual Medicine*, **2010**, 7, 1321-3	1.1	2
114	Endothelin-1 induces contraction of female rat internal pudendal and clitoral arteries through ET(A) receptor and rho-kinase activation. *Journal of Sexual Medicine*, **2010**, 7, 2096-2103	1.1	15
113	Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: a randomized placebo-controlled trial. *Journal of Sexual Medicine*, **2010**, 7, 2209-2216	1.1	20
112	The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. **2010**, 22, 291-7		9
111	8-isoprostane F2□up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide. *BJU International*, **2010**, 106, 1794-8	5.6	7
110	A Review of the Pathophysiology and Novel Treatments for Erectile Dysfunction. **2010**, 2010,		17
109	Erectile dysfunction. **2010**, 182, 381-2		2
108	Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds. *Handbook of Experimental Pharmacology*, **2011**, 93-133	3.2	45
107	Phosphodiesterase 5 inhibitors attenuate renal tubular apoptosis after partial unilateral ureteral obstruction: an experimental study. **2011**, 27, 15-9		10
106	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. **2011**, 63, 811-59		213
105	Contemporary Treatment of Erectile Dysfunction. **2011**,		2
104	Methylxanthines. *Handbook of Experimental Pharmacology*, **2011**,	3.2	18
103	Autonomic Dysfunction in Neuromuscular Disorders. **2011**, 61-77		2

102	Silencing MaxiK activity in corporal smooth muscle cells initiates compensatory mechanisms to maintain calcium homeostasis. *Journal of Sexual Medicine*, **2011**, 8, 2191-204	1.1	7
101	Einführung in die Sexualmedizin. **2011**, 71, R18-R34		
100	Dysfonction Érectile. **2011**, 917-922		
99	Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. **2011**, 91, 651-90		443
98	Role of hydrogen sulfide in the physiology of penile erection. **2012**, 33, 529-35		19
97	Primary Care Evaluation and Treatment of Erectile Dysfunction. **2012**, 105-119		1
96	Erectile Dysfunction. **2012**, 1339-1346		
95	Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. **2012**, 53, 377-85		8
94	Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272. **2012**, 688, 49-55		7
93	How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. *Journal of Sexual Medicine*, **2012**, 9, 26-33	1.1	24
92	Poly(ADP-ribose) polymerase inhibition improves erectile function by activation of nitric oxide/cyclic guanosine monophosphate pathway in diabetic rats. *Journal of Sexual Medicine*, **2012**, 9, 1319-27	1.1	8
91	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. *BJU International*, **2012**, 110, 1801-6	5.6	37
90	Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction. **2013**, 386, 805-11		15
89	Dysfonction Érectile. *Canadian Journal of Diabetes*, **2013**, 37, S648	2.1	
88	Male erectile dysfunction: integrating psychopharmacology and psychotherapy. **2013**, 35, 33-8		22
87	PDE5 inhibitors: considerations for preference and long-term adherence. *International Journal of Clinical Practice*, **2013**, 67, 768-80	2.9	73
86	Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. **2013**, 13, 189-96		28
85	Erectile dysfunction. *Canadian Journal of Diabetes*, **2013**, 37 Suppl 1, S150-2	2.1	6

84	Dysfonction Erectile. *Canadian Journal of Diabetes*, **2013**, 37, S528-S530	2.1	
83	Erectile Dysfunction. *Canadian Journal of Diabetes*, **2013**, 37, S337	2.1	
82	Superoxide anion production by NADPH oxidase plays a major role in erectile dysfunction in middle-aged rats: prevention by antioxidant therapy. *Journal of Sexual Medicine*, **2013**, 10, 960-71	1.1	35
81	Erectile Dysfunction: The Medical Treatment. **2013**, 12, 13-17		3
80	Erectile dysfunction. **2013**, 381, 153-65		545
79	Assessment of the efficacy of combination therapy with folic acid and tadalafil for the management of erectile dysfunction in men with type 2 diabetes mellitus. *Journal of Sexual Medicine*, **2013**, 10, 1146-50	1.1	20
78	Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension. **2013**, 14, 265-269		20
77	Phosphodiesterase-9 (PDE9) inhibition with BAY 73-6691 increases corpus cavernosum relaxations mediated by nitric oxide-cyclic GMP pathway in mice. **2013**, 25, 69-73		12
76	Alprostadil for the treatment of impotence. *Expert Opinion on Pharmacotherapy*, **2014**, 15, 421-8	4	38
75	New approaches to the design and discovery of therapies to prevent erectile dysfunction. **2014**, 9, 1447-69		10
74	Physiology of Erection. **2014**, 1-12		
73	Men's Sexual Health and Fertility. **2014**,		7
72	Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. *Hypertension*, **2014**, 63, 5-11	8.5	28
71	Radical Prostatectomy. **2014**,		3
70	Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry. *Methods and Principles in Medicinal Chemistry*, **2014**, 9-28	0.4	
69	Editorial comment to extracorporeal shockwave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. *International Journal of Urology* , **2014**, 21, 1045	2.3	
68	Regional cerebral blood flow following single-dose and continuous-dose tadalafil after stroke. *Acta Neurologica Scandinavica*, **2014**, 130, 380-6	3.8	7
67	Effect of HGF on the apoptosis of rat corpus cavernosum smooth muscle cells induced by TGF1. *Andrologia*, **2015**, 47, 1020-7	2.4	3

66	Effect of non-antihypertensive drugs on endothelial function in hypertensive subjects evaluated by flow-mediated vasodilation. *Current Vascular Pharmacology*, **2015**, 13, 121-7	3.3	4
65	The Challenge of Erectile Dysfunction Management in the Young Man. *Current Urology Reports*, **2015**, 16, 84	2.9	21
64	Hepatocyte growth factor-modified adipose tissue-derived stem cells improve erectile function in streptozotocin-induced diabetic rats. *Growth Factors*, **2015**, 33, 282-9	1.6	23
63	Ginsenoside Rg3 improves erectile function in streptozotocin-induced diabetic rats. *Journal of Sexual Medicine*, **2015**, 12, 611-20	1.1	15
62	Nanovesicular carrier-mediated transdermal delivery of tadalafil: i-formulation and physicsochemical characterization. *Drug Development and Industrial Pharmacy*, **2015**, 41, 714-21	3.6	15
61	Improvement of erectile dysfunction by the active pepide from Urechis unicinctus by high temperature/pressure and ultra - wave assisted lysis in Streptozotocin Induced Diabetic Rats. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2016**, 42, 825-37	2	5
60	Erectile dysfunction and infertility. **2016**, 152-171		1
59	Advances in pharmacotherapy for erectile dysfunction and associated cardiac impact. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2281-2289	4	1
58	Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment. *Journal of Pharmacology and Experimental Therapeutics*, **2016**, 359, 230-237	4.7	19
57	Contemporary Treatment of Erectile Dysfunction. *Contemporary Endocrinology*, **2016**,	0.3	2
56	Effects of Caffeine on Olfactory Learning in Crickets. *Zoological Science*, **2016**, 33, 513-519	0.8	7
55	PDE5A Polymorphisms Influence on Sildenafil Treatment Success. *Journal of Sexual Medicine*, **2016**, 13, 1104-10	1.1	3
54	Sildenafil obviates ischemia-reperfusion injury-induced acute kidney injury through peroxisome proliferator-activated receptor □agonism in rats. *Journal of Surgical Research*, **2016**, 201, 69-75	2.5	21
53	The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review. *Urology*, **2017**, 105, 54-61	1.6	14
52	Phosphodiesterase 5 inhibition ameliorates angiotensin II-dependent hypertension and renal vascular dysfunction. *American Journal of Physiology - Renal Physiology*, **2017**, 312, F474-F481	4.3	22
51	Erectile Dysfunction in Young Men-A Review of the Prevalence and Risk Factors. *Sexual Medicine Reviews*, **2017**, 5, 508-520	5.6	100
50	Incontinence and Sexual Dysfunction. **2018**, 389-416		
49	Sexual Dysfunction and Hypogonadism in Men With Diabetes. *Canadian Journal of Diabetes*, **2018**, 42 Suppl 1, S228-S233	2.1	11

48	Erectile Dysfunction. **2018**, 623-629.e2		
47	The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism. *Endocrine*, **2018**, 59, 602-613	4	10
46	Preventing Erectile Dysfunction after Radical Prostatectomy: Nerve-Sparing Techniques, Penile Rehabilitation, and Novel Regenerative Therapies. **2019**,		1
45	Alkaloid extracts from Bitter leaf (Vernonia amygdalina) and Black nightshade (Solanum nigrum) inhibit phosphodiesterase-5, arginase activities and oxidative stress in rats penile tissue. *Journal of Food Biochemistry*, **2019**, 43, e12889	3.3	3
44	Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. *Arab Journal of Urology Arab Association of Urology*, **2020**, 18, 54-58	1.7	3
43	Is there a role for phosphodiesterase inhibitors in the treatment of male subfertility?. *Human Fertility*, **2020**, 1-11	1.9	
42	The treatment rate of erectile dysfunction (ED) in younger men with type 2 diabetes is up to four times higher than the equivalent non-diabetes population. *International Journal of Clinical Practice*, **2020**, 74, e13538	2.9	0
41	Elevated pigment epithelium-derived factor induces diabetic erectile dysfunction via interruption of the Akt/Hsp90/eNOS complex. *Diabetologia*, **2020**, 63, 1857-1871	10.3	3
40	Erectile Dysfunction: an Integrative Approach.		
39	Effects of different vardenafil doses on bone healing in a rat fracture model. *Joint Diseases and Related Surgery*, **2021**, 32, 313-322	1.3	
38	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. *Journal of Personalized Medicine*, **2021**, 11,	3.6	5
37	Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions. *Clinical Pharmacology in Drug Development*, **2021**,	2.3	1
36	Autonomic Dysfunction in Neuromuscular Disorders. **2022**, 97-117		
35	Erectile dysfunction and lower urinary tract. *Handbook of Experimental Pharmacology*, **2009**, 507-31	3.2	12
34	Rehabilitation. **2014**, 63-98		0
33	Evaluation and Management of Erectile Dysfunction. **2012**, 721-748.e7		6
32	Phosphodiesterase 5. **2006**,		8
31	Sympathetic Hyperactivity, Increased Tyrosine Hydroxylase and Exaggerated Corpus Cavernosum Relaxations Associated with Oxidative Stress Plays a Major Role in the Penis Dysfunction in Townes Sickle Cell Mouse. *PLoS ONE*, **2016**, 11, e0166291	3.7	9

30	PDE-5 inhibitors should be used post radical prostatectomy as erection function rehabilitation? | Opinion: Yes. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2017**, 43, 385-389	2	3
29	An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. *Asian Journal of Andrology*, **2015**, 17, 61-7	2.8	12
28	Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. *Indian Journal of Endocrinology and Metabolism*, **2015**, 19, 451-61	1.7	24
27	Oral Pharmacokinetics of Mirodenafil in Mexican Healthy Volunteers. *Pharmacology & Pharmacy*, **2014**, 05, 112-116	0.3	1
26	Rehabilitation. **2009**, 283-313		
25	Erectile Dysfunction. **2009**, 839-844		
24	Men's Health Topics. **2010**, 752-769		
23	Oral Therapy for Erectile Dysfunction. **2011**, 93-106		0
22	Erectile Dysfunction. **2012**, 560-566.e2		
21	Postoperative Management: Erectile Function. **2014**, 167-188		
20	Erectile Dysfunction and Infertility. **2014**, 89-117		
19	Oral Prescription Therapy for Erectile Dysfunction. *Contemporary Endocrinology*, **2016**, 163-173	0.3	0
18	In Vivo Tracking of Mesenchymal Stem Cell in Rat Genitalia with Erectile Dysfunction Labeled by Superparamagnetic Iron Oxide Using Magnetic Resonance Imaging and Its Therapeutic Effect. *Iranian Journal of Radiology*, **2018**, 15,	1.4	
17	Rehabilitation in der Uroonkologie: Erektile Dysfunktion. *Springer Reference Medizin*, **2020**, 1-9	0	
16	Development and Characterization of Spray-dried Amorphous Solid Dispersion of Sildenafil: In vivo Evaluation. *International Journal of Pharmacology*, **2020**, 16, 460-469	0.7	3
15	Pharmacology of Male Sexual Function. **2020**, 159-174		
14	Rehabilitation. **2007**, 203-228		1
13	Rehabilitation. **2014**, 63-98		0

12	Evaluation and Management of Erectile Dysfunction. **2021**, 93-126		
11	Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction. *Patient Preference and Adherence*, **2008**, 2, 149-55	2.4	7
10	Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. *American Journal of Cancer Research*, **2015**, 5, 3311-24	4.4	33
9	THE SCIENCE AND PRACTICE OF ERECTION PHYSIOLOGY: STORY OF A REVOLUTIONARY GASEOUS MOLECULE. *Transactions of the American Clinical and Climatological Association*, **2019**, 130, 51-59	0.9	4
8	A single-centre result of two courses of low-intensity shockwave therapy (Li-SWT) in erectile dysfunction. *Andrologia*, **2021**, e14324	2.4	1
7	Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: A systematic review.. *Life Sciences*, **2022**, 291, 120270	6.8	
6	Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.. *International Journal of Urology*, **2022**,	2.3	1
5	A Review on Phosphodiesterase-5 Inhibitors as a Topical Therapy for Erectile Dysfunction.. *Sexual Medicine Reviews*, **2022**,	5.6	1
4	Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma. *Journal of Cancer Research and Clinical Oncology*,	4.9	1
3	Single-cell transcriptome atlas of the human corpus cavernosum. **2022**, 13,		0
2	Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: Implication for priapism in sickle cell disease. **2022**, 36,		0
1	An overview of the history, current strategies, and potential future treatment approaches in erectile dysfunction: a comprehensive review.		0